Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
  • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
  • A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B17/00—Surgical instruments, devices or methods
  • A61B17/00491—Surgical glue applicators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
  • A61L24/001—Use of materials characterised by their function or physical properties
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B17/00—Surgical instruments, devices or methods
  • A61B17/00491—Surgical glue applicators
  • A61B2017/005—Surgical glue applicators hardenable using external energy source, e.g. laser, ultrasound

Definitions

• the present invention belongs to the field of surgical glues, more particularly the present invention relates to compositions for use in a method for adhesion of biological tissue to one another, for adhesion of a material to a biological tissue, for the adhesion of an adhesive or substance to the surface of a biological tissue, for sealing an orifice (hemostasis, aerostasis) in a biological tissue, for strengthening a biological tissue and / or for fixing and stabilizing a biological tissue .
• surgical glues have very low adhesive properties and therefore can not be used as an adhesive or as a surgical suture.
• the application of surgical glues is most of the time directly on the fabric, without preparation of the bonding surface.
• the penetration into the tissues is weak or non-existent, which leads to poor quality bonding.
• Applicants have found that current glues do not stick or penetrate the tissues. As a result, they have developed a glue capable of penetrating deep into the area of the biological tissue in order to anchor the glue in the fabric.
• document EP1994886A1 discloses a surgical glue comprising polymerizable monomers of the cyanoacrylate family.
• the polymerization of the latter is triggered by the moisture of the biological tissue as soon as contact is made between the surgical glue and the latter. Therefore, despite the low viscosity of this surgical glue, the polymerization of the cyanoacrylate monomers takes place on the surface of the biological tissue. Thus, the cyanoacrylate monomers can not penetrate the biological tissue. The cyanoacrylate monomers can not be anchored in the tissue, which explains the low mechanical strength and low clinical efficacy of cyanoacrylate surgical glues.
• the present invention proposes to provide a new type of surgical glues.
• the compositions and the process according to the invention make it possible to obtain an effective and resistant bonding.
• the breakage of the bonding is done by the propagation of a crack in the bonded fabric or in the glue joint and not at the glue-fabric interface. Bonding is applicable to all types of biological tissues (soft tissues, bones). Such bonding also makes it possible to obtain effective haemostasis or aerostasis. It also allows to replace the surgical suture by a collage.
• the principle of the invention is to allow a polymerizable monomer to penetrate into the biological tissue to allow anchoring of the polymer in the tissue thereby enhancing the adhesion properties to the tissue surface.
• the present invention relates to a composition for use in a process for the adhesion of between them, for the adhesion of a material to a biological tissue, for the adhesion of an adhesive or a substance to the surface of a biological tissue, for sealing an orifice (hemostasis, aerostasis) in a biological tissue, for reinforcing a biological tissue and / or for fixing and stabilizing a biological tissue, characterized in that it comprises a polymerizable monomer under the effect of ultraviolet (UV) radiation and in that its viscosity is less than 10 mPa.s at 20 ° C.
• UV ultraviolet
• the present invention also relates to a composition for use in a method for adhesion of biological tissues to one another, for adhesion of a material to a biological tissue, for adhesion of an adhesive or substance to the surface of a biological tissue, for sealing an orifice (hemostasis, aerostasis) in a biological tissue, for reinforcing a biological tissue and / or for fixing and stabilizing biological tissue, which is remarkable in that it comprises a polymerizable monomer under effect of ultraviolet (UV) radiation and that its viscosity is less than 10 mPa.s at 20 ° C.
• UV ultraviolet
• the viscosity of the composition may in particular be measured by a falling ball viscometer according to DIN53015.
• the term "polymerizable monomer” means a monomer whose polymerization can be initiated under the effect of ultraviolet (UV) radiation.
• UV radiation ultraviolet
• the polymerization of the composition according to the invention can be initiated only by ultraviolet radiation to the exclusion of any other mode of initiation.
• the initiation of the polymerization of the polymerizable monomers consists of irradiation by UV radiation.
• said UV radiation has a wavelength of between 150 nm to 280 nm, even more preferably between 170 nm to 260 nm and quite preferably between 190 nm and 240 nm.
• said UV radiation has a wavelength of between 200 nm and 400 nm, even more preferably between 300 nm and 400 nm and quite preferably between 350 nm and 400 nm.
• the polymer obtained after polymerization of the monomer is preferably a biocompatible polymer.
• composition according to the invention does not comprise polymerizable monomers whose polymerization can be initiated at the single contact of water molecules. This avoids the instantaneous polymerization of the composition according to the invention in contact with the tissues.
• composition according to the invention does not comprise polymerizable monomers of the family of cyanoacrylates known to polymerize rapidly in contact with water and / or ambient humidity.
• the polymerizable monomer is only polymerizable by irradiation with UV radiation.
• said viscosity is less than 6 mPa.s at 20 ° C. According to an even more preferred embodiment, said viscosity is less than 4 mPa.s at 20 ° C.
• said viscosity is less than 2 mPa.s at 20 ° C and more particularly between 1 and 2 mPa.s at 20 ° C.
• the composition according to the invention is not a hydrogel.
• said monomer is a methacrylate acrylate monomer or an acrylate or methacrylate oligomer.
• said monomer comprises a polar function.
• polar function refers to a group of atoms in which the electrons are distributed asymmetrically, thus allowing this polar function to participate in electrostatic interactions.
• Said polar function can in particular be chosen from the group comprising the hydroxyl, amide, carboxyl, amino, carbonate, carbamate, sulfonamide, sulfonic, phosphonic, methoxyethyl, methoxyethoxyethyl, hydroxyethyl and hydroxyethoxyethyl functions.
• said acrylate monomer is selected from the group consisting of mono-, di-, tri-, tetra- and penta-acrylate or methacrylate, and mixtures thereof.
• said acrylate monomer is chosen from the group comprising acrylic acid and methyl methacrylate; dimethylaminoethyl methacrylate; ethyl acrylate; cyclohexyl methacrylate; 2-hydroxyethyl methacrylate; 3-hydroxypropyl acrylate; alpha-bromoethyl acrylate; alpha-chloroethyl acrylate; the chloromethyl methacrylate; 2-bromoethyl methacrylate; 2-naphthyl methacrylate; paratolyl acrylate; parachlorophenyl methacrylate; metabromophenyl acrylate; 2,4,6-tribromophenyl acrylate; parachlorobenzyl methacrylate; metamethoxybenzyl methacrylate; paraethylbenzyl acrylate; 1,6-hexanediol di methacrylate; neopentyl glyco
• said acrylate monomer is chosen from the group 1 'hydroxyethyl) methacrylate, acrylic acid,
• said acrylate monomer is chosen from the group comprising acrylic acid, 1 '(hydroxyethyl) methacrylate,
• said acrylate monomer is selected from the group consisting of acrylic acid, tert-butyl acrylate and mixtures thereof. According to another most preferred embodiment, said acrylate monomer is selected from the group consisting of acrylic acid, dimethylaminoethyl methacrylate and mixtures thereof.
• said monomer has a molar mass of between 50 and 300 g. mol -1 .
• said monomer has a concentration of between 90 and 100% by weight relative to the total mass of the composition.
• said composition further comprises a reticulating agent.
• said composition comprises only said monomer or said monomer and a retaining agent.
• said crosslinking agent comprises an acrylate function.
• said crosslinking agent is chosen from the group comprising multi-functional acrylates including in particular 1,6-hexanediol di acrylate, trimethylolpropane tri acrylate, 1,2-ethylene glycol di acrylate, pentaerythritol tetracrylate and mixtures thereof.
• said crosslinking agent is chosen from the group comprising multi-functional acrylates including hexanediol dimethylacrylate (HDDMA), ethylene glycol dimethylacrylate (EGDMA), butanediol diacrylate (BDDA) ,, poly (ethylene glycol) diacrylate (PEGDA) and mixtures thereof.
• HDDMA hexanediol dimethylacrylate
• ELDMA ethylene glycol dimethylacrylate
• BDDA butanediol diacrylate
• PEGDA poly (ethylene glycol) diacrylate
• said crosslinking agent is present at a concentration of between 1% and 5% by weight, even more preferably between 1 and 3% by weight, still more preferably between 1 and 2% by weight relative to the total mass of the composition.
• said crosslinking agent is present at a concentration of between 0.1 and 3% by weight, even more preferably between 0.1 and 0.5% by weight, still more preferably between 0.1 and 0.3% by weight and quite preferably at a concentration of 0.2% by weight relative to the total mass of the composition.
• the composition according to the invention comprises a photoinitiator.
• a photoinitiator The skilled person will choose according to the emission spectrum of the lamp used the most suitable photoinitiator.
• the photoinitiator may be chosen from: 2,2-dimethoxyphenyl-2-acetophenone (DMPA) camphorquinone or 4,4'-bis (diethylamino) enzophenone, this list being non-limiting.
• DMPA 2,2-dimethoxyphenyl-2-acetophenone
• 4,4'-bis (diethylamino) enzophenone this list being non-limiting.
• the photoinitiator is used at a concentration of between 0.2 and 1%, preferably between 0.2 and 0.3% by weight.
• said light ⁇ initiator is DMPA.
• said composition comprises a solvent and even more preferably said solvent is water.
• said solvent is an alcohol and quite preferably ethanol.
• said composition is devoid of solvent.
• compositions means that the composition according to the invention includes the elements mentioned.
• present invention relates to compositions comprising only the elements cited to the exclusion of any other.
• the present invention also relates to a method for the adhesion of biological tissues to one another, for the adhesion of a material to a biological tissue, for the adhesion of an adhesive or a substance to the surface of a tissue.
• biological for closing an orifice (hemostasis, aerostasis) in a biological tissue, for strengthening a biological tissue and / or for setting and stabilizing a biological tissue, remarkable in that it comprises the steps:
• the method according to the invention is advantageously non-invasive.
• non-invasive means that the method according to the invention does not include any surgical step of accessing the tissue to be treated.
• the method according to the invention is implemented on a biological tissue directly accessible (e.g. the skin) or previously made accessible by other methods.
• the characteristics of the UV radiation used are adapted to the constituents of the composition, in particular to the nature of the polymerizable monomer and to its concentration in the composition.
• said method further comprises after step (iii), a step (iv) of apposition of a synthetic fabric to the surface of the fabric.
• said UV radiation has a wavelength of between 150 and 280 nm. According to a preferred embodiment, said UV radiation has a power of between 100 and 200 W.
• the present invention also relates to a set of parts comprising a composition according to the invention and a source of UV radiation.
• the UV radiation source of the set of parts can emit UV radiation suitable for polymerizing and / or aiding the polymerization and / or accelerating the polymerization of the polymerizable monomer of the composition.
• UV radiation source refers to any artificial means capable of producing UV radiation and more particularly a radiation of wavelength lying in the range 150 nm to 280 nm, even more preferably in the range 170 nm to 260 nm and most preferably in the range 190 nm to 260 nm. nm and 240 nm.
• said UV radiation is of power between 0.5 W and 200W and quite preferentially between 100 and 200W.
• UV radiation source refers to any artificial means capable of producing UV radiation with a wavelength of between 200 nm and 400 nm, and even more preferably between 300 nm at 400 nm and quite preferably between 350 nm and 400 nm.
• said UV radiation has a wavelength of between 150 and 280 nm and a power of between 100 and 200 W.
• Acrylic / (Hydroxyethyl) methacrylate / crosslinking agents, or acrylic acid / dimethylaminoethyl methacrylate / crosslinking agents of viscosity and varying concentrations were deposited on bovine pericardial samples. This step is carried out at 20 ° C. These pericardial samples were subjected to 150 W UV radiation for a period of 5 minutes to initiate polymerization of the monomers. The radiation source was placed 10 cm from the pericardium.
• the pericardial samples were subjected to UV radiation under conditions identical to those of the previous step.
• a peel test was then performed by pulling 180 ° on the fiberglass strip in a controlled oven at 37 ° C.
• the rest time of the belt installed between the jaws of the traction machine is one minute, the temperature within the sample is, at the time of the test start, 30 ° C + or - 4 ° C.
• a solution of acrylic acid was deposited on pericardial samples. Said pericardial samples were subjected to 150 W UV radiation for 5 min., to trigger the polymerization of the monomers. The radiation source was placed 10 cm from the pericardium.
• the pericardial samples were then cut transversely and observed by scanning electron microscopy.
• breaking strength i.e. the resistance of the bonding
• compositions used All Viscosity [mPa.s] Resistance to rupture F / b the compositions comprise [N / m] in the pericardium 0.25% by weight of DMPA)
• the presence of the formed polymer infiltrated in the surface of the fabric is observed at a depth of 50 ⁇ m. It is furthermore observed that the polymer formed has penetrated into the spaces between the collagen fibers of the tissues.

Landscapes

• Health & Medical Sciences (AREA)
• Surgery (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Materials Engineering (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Biomedical Technology (AREA)
• Heart & Thoracic Surgery (AREA)
• Medical Informatics (AREA)
• Molecular Biology (AREA)
• Materials For Medical Uses (AREA)
• Medicinal Chemistry (AREA)
• Polymers & Plastics (AREA)
• Organic Chemistry (AREA)
• Adhesives Or Adhesive Processes (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=54140580

Family Applications (1)

Country Status (9)

Cited By (3)

Families Citing this family (3)

Citations (3)

Family Cites Families (17)

• 2015
  • 2015-05-21 FR FR1554583A patent/FR3036288B1/fr active Active
• 2016
  • 2016-05-20 US US15/575,678 patent/US11207443B2/en active Active
  • 2016-05-20 WO PCT/FR2016/051211 patent/WO2016185153A1/fr not_active Ceased
  • 2016-05-20 CN CN201680029436.0A patent/CN107771086B/zh active Active
  • 2016-05-20 AU AU2016263552A patent/AU2016263552A1/en not_active Abandoned
  • 2016-05-20 ES ES16732691T patent/ES2908874T3/es active Active
  • 2016-05-20 CA CA2986308A patent/CA2986308A1/fr active Pending
  • 2016-05-20 JP JP2017560619A patent/JP7019884B2/ja active Active
  • 2016-05-20 EP EP16732691.7A patent/EP3297692B1/fr active Active
• 2021
  • 2021-12-27 US US17/562,381 patent/US12239759B2/en active Active
• 2025
  • 2025-01-27 US US19/037,365 patent/US20250170299A1/en active Pending

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events